
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is attractive because its Lead-212 platform offers a differentiated radiopharmaceutical mechanism with high tumor-killing potency and potentially lower off-target toxicity, while the pipeline spans multiple cancer settings that broaden commercial optionality. Recent data from bamzireotide navoxetan in SSTR2+ NETs showed 37%/47% ORR, 92%/100% DCR, and 75% pooled 18-month PFS across Cohorts 1-3, and lapemelanotide zapixetar also showed a 25% confirmed response rate with no DLTs or treatment-related discontinuations. The company ended 3Q26 with about $202MM in cash and investments, expects funding into 2028, and has key catalysts ahead in 1Q27, 2027, and early 2027 manufacturing completion that could further de-risk the story.
Bears say
Perspective Therapeutics is viewed negatively because the company faces a broad set of fundamental risks, including product commercialization and supply chain exposure, concentration risk, clinical and regulatory uncertainty, liquidity pressure, and partnership, legal, intellectual property, macroeconomic, and geopolitical risk. Its valuation is especially vulnerable to poorer-than-expected clinical data, since adverse trial outcomes could materially weaken the market potential and economics of its product candidates. Longer term, intensifying competition and the possibility of unfavorable reimbursement or slow adoption of marketed products could further impair commercial execution and delay any path to durable value creation.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Perspective Therapeutics Inc (CATX) Forecast
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares